Results 151 to 160 of about 3,283,768 (383)
MIF as an oncogenic driver of low‐heterogeneity melanomas
Molecular Oncology, EarlyView.Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran +4 more
wiley +1 more source
Modelling Immunological Memory [PDF]
In Silico Immunology, 83-108, 2006, 2010 Accurate immunological models offer the possibility of performing highthroughput experiments in silico that can predict, or at least suggest, in vivo phenomena. In this chapter, we compare various models of immunological memory. We first validate an experimental immunological simulator, developed by the authors, by simulating several theories of ...
arxiv
The architecture of co-culture spheroids regulates tumor invasion within a 3D extracellular matrix [PDF]
arXiv, 2020 Tumor invasion, the process by which tumor cells break away from their primary tumor and gain access to vascular systems, is an important step in cancer metastasis. Most current 3D tumor invasion assays consisted of single tumor cells embedded within an extracellular matrix (ECM). These assays taught us much of what we know today on how key biophysical
arxiv
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez +17 more
wiley +1 more source
JTM's Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section. [PDF]
, 2013 For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor Immunology and Biological Cancer Therapy. Under the editorial leadership of Dr.
Bot, A., Marincola, F., Romero, P.
core +3 more sources
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Journal of Immunotherapy for Cancer, 2015 The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century.
D. Page +12 more
semanticscholar +1 more source
Understanding and measuring mechanical signals in the tumor stroma
FEBS Open Bio, EarlyView.This review discusses cancer‐associated fibroblast subtypes and their functions, particularly in relation to extracellular matrix production, as well as the development of 3D models to study tumor stroma mechanics in vitro. Several quantitative techniques to measure tissue mechanical properties are also described, to emphasize the diagnostic and ...
Fàtima de la Jara Ortiz +3 more
wiley +1 more source
Correction to: CART cells are prone to Fas- and DR5-mediated cell death
Journal for ImmunoTherapy of Cancer, 2018 After publication of this article [1], it was noticed that 3 authors were missed from the author list.
Benjamin O. Tschumi +10 more
doaj +1 more source
MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma [PDF]
, 2018 Natural killer (NK) cells are immune innate effectors playing a pivotal role in the immunosurveillance of multiple myeloma (MM) since they are able to directly recognize and kill MM cells.
Achour, Adnane +18 more
core +1 more source
Special Conference on Tumor Immunology and Immunotherapy: A New Chapter
Cancer immunology research, 2015 The overall objective of the fifth American Association for Cancer Research Special Conference, “Tumor Immunology and Immunotherapy: A New Chapter,” organized by the Cancer Immunology Working Group, was to highlight multidisciplinary approaches of ...
Katelyn T Byrne +3 more
semanticscholar +1 more source